Lars J.S. Knutsen, MA, PhD, FRSC leads Discovery Pharma Consulting LLC, a R&D Consulting group based both in West Chester, PA, US and Cambridge UK, providing Drug Discovery and I.P. Expert Witness services. Lars began his Pharma R&D career at Glaxo in Herts., UK after completing an M.A. in Chemistry at Christ Church, Oxford. At Glaxo, he gained a Nucleoside Medicinal Chemistry Ph.D. (antivirals) then joined Novo Nordisk, Copenhagen in 1986. In the Novo CNS R&D Group he led projects that identified GABA uptake inhibitor Tiagabine, an anticonvulsant approved by FDA in 1997 and initiated a project providing adenosine agonist drug candidates for stroke. Lars was appointed Associate Director, Med. Chem. at Vernalis PLC (UK), where he initiated several projects, including the adenosine A2A antagonist effort leading to V2006/BIIB014 that exhibited Phase IIA PoC in Parkinson’s Disease. In 2001 he was appointed Director of Chemistry at Ionix Pharma in Cambridge, the UK’s first pain-focused biotech, moving to Cephalon R&D in West Chester, PA, US in 2005. As the first Distinguished Scientist he invented Irdabisant, the H3 antagonist, clinically investigated for cognitive disorders at Teva (US). Lars now serves as consultant VP, Med. Chem. at NMD Pharma, Denmark where he designed clinically investigated ClC-1 blockers NMD670 and NMD1343: https://www.nmdpharma.com/pipeline Lars was Adjunct Professor at Drexel University College of Medicine from 2009-19, and lectures widely on Drug Discovery. Discovery Pharma Consulting, founded in 2009, guides Pharma/Biotech firms as well as academic R&D teams in drug design and discovery. The company provides Expert Input to Law Firms in IP litigation. Lars holds UK & US passports and completed 18 Pharma IP cases since 2011; he and his team of consultants is available to consult worldwide.